Onkológia 6/2017

Experience with obinutuzumab in patients with chronic lymphocy

Objective: The main objective of our case report is to present a case of an elderly patient with chronic lymphocytic leukemia and our experience with the use of a new type 2 anti-CD20 monoclonal antibody. Case report: We describe a treatment of an 84-year-old patient with chronic lymphocytic leukemia. The patient was treated with a type 2 anti-CD20 monoclonal antibody in combination with chlorambucil. The patient had benefit from the treatment, even though she have not not achieved a minimal residual disease negativity. Conclusion: Older, co-morbid patients with chronic lymphocytic leukemia can not be treated with conventional chemoimmunotherapy regimens. The goal of the treatment of these patients is a prolonged survival and to maintain quality of life with a minimum of adverse effects.

Keywords: chronic lymphocytic leukemia, CLL, obinutuzumab, chlorambucil